Health
Moderna’s cancer vaccine is ‘likely’ to get approved. Skeptics question if it will be the best option.
By Marcus Chen
MarketWatch
New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.
Up nextModerna’s cancer vaccine is ‘likely’ to get approved. Skeptics question if it will be the best option.Health · 1 min read
